About the Study The study analyzed a dataset generated by linking more than a half million de-identified patients who received the GeneSight test to administrative insurance claim ...

In a report released yesterday, Puneet Souda from Leerink Partners maintained a Hold rating on Myriad Genetics (MYGN – Research Report). The ...

Myriad Genetics, Inc. announced that a study published in the Journal of Clinical Psychopharmacology found that the GeneSight® Psychotropic Test significantly reduced psychiatric hospitalizations ...

In the assessment of 12-month price targets, analysts unveil insights for Myriad Genetics, presenting an average target of ...

Myriad Genetics Offers Many Types of Molecular Tests Its top seller is the MyRisk Hereditary cancer test, which evaluates 48 genes to help identify a patient's risk of developing 11 different ...

BofA lowered the firm’s price target on Myriad Genetics (MYGN) to $9 from $11 and keeps an Underperform rating on the shares.

In the preceding three months, 10 analysts have released ratings for Myriad Genetics MYGN, presenting a wide array of perspectives from bullish to bearish. Summarizing their recent assessments ...

SALT LAKE CITY, April 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that the Journal of ...